[go: up one dir, main page]

SE9801494D0 - Novel use - Google Patents

Novel use

Info

Publication number
SE9801494D0
SE9801494D0 SE9801494A SE9801494A SE9801494D0 SE 9801494 D0 SE9801494 D0 SE 9801494D0 SE 9801494 A SE9801494 A SE 9801494A SE 9801494 A SE9801494 A SE 9801494A SE 9801494 D0 SE9801494 D0 SE 9801494D0
Authority
SE
Sweden
Prior art keywords
novel use
relates
inflammatory agents
pharmaceutical compounds
certain pharmaceutical
Prior art date
Application number
SE9801494A
Other languages
English (en)
Inventor
Aziz Asghar
Original Assignee
Astra Pharma Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Pharma Prod filed Critical Astra Pharma Prod
Priority to SE9801494A priority Critical patent/SE9801494D0/sv
Publication of SE9801494D0 publication Critical patent/SE9801494D0/sv
Priority to ARP990101817A priority patent/AR016212A1/es
Priority to MYPI99001635A priority patent/MY121063A/en
Priority to KR1020007011958A priority patent/KR100569777B1/ko
Priority to DE69918541T priority patent/DE69918541T2/de
Priority to JP2000545521A priority patent/JP2002512955A/ja
Priority to HK01104450.4A priority patent/HK1033876B/en
Priority to AU41793/99A priority patent/AU4179399A/en
Priority to PCT/SE1999/000701 priority patent/WO1999055322A1/en
Priority to US09/380,988 priority patent/US6221887B1/en
Priority to DK99947024T priority patent/DK1073431T3/da
Priority to NZ507436A priority patent/NZ507436A/en
Priority to PT99947024T priority patent/PT1073431E/pt
Priority to AU43024/99A priority patent/AU760783B2/en
Priority to CA002329328A priority patent/CA2329328A1/en
Priority to AT99947024T priority patent/ATE270545T1/de
Priority to DE69918972T priority patent/DE69918972T2/de
Priority to ES99947024T priority patent/ES2221753T3/es
Priority to PCT/SE1999/000702 priority patent/WO1999055323A1/en
Priority to AT99925537T priority patent/ATE271861T1/de
Priority to EP99925537A priority patent/EP1073430B1/en
Priority to IL13891999A priority patent/IL138919A0/xx
Priority to JP2000545522A priority patent/JP2002512956A/ja
Priority to CNB998078182A priority patent/CN1200702C/zh
Priority to SI9930647T priority patent/SI1073431T1/xx
Priority to EP99947024A priority patent/EP1073431B1/en
Priority to BR9909971-3A priority patent/BR9909971A/pt
Priority to TW088113888A priority patent/TW570793B/zh
Priority to SA99200482A priority patent/SA99200482B1/ar
Priority to NO20005386A priority patent/NO20005386D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE9801494A 1998-04-28 1998-04-28 Novel use SE9801494D0 (sv)

Priority Applications (30)

Application Number Priority Date Filing Date Title
SE9801494A SE9801494D0 (sv) 1998-04-28 1998-04-28 Novel use
ARP990101817A AR016212A1 (es) 1998-04-28 1999-04-20 Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
MYPI99001635A MY121063A (en) 1998-04-28 1999-04-27 Use of nmda antagonists for treatment of irritable bowel syndrome
BR9909971-3A BR9909971A (pt) 1998-04-28 1999-04-28 Uso de um composto, processo para tratamento ou prevenção da sìndrome de intestinos irritáveis, e, composição farmacêutica para o tratamento da sìndrome dos intestinos irritáveis
CA002329328A CA2329328A1 (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome
DE69918972T DE69918972T2 (de) 1998-04-28 1999-04-28 Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
JP2000545521A JP2002512955A (ja) 1998-04-28 1999-04-28 炎症疾患の治療のためのｎｍｄａアンタゴニストおよび／またはナトリウムチャンネルアンタゴニストの使用
HK01104450.4A HK1033876B (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome
AU41793/99A AU4179399A (en) 1998-04-28 1999-04-28 Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
PCT/SE1999/000701 WO1999055322A1 (en) 1998-04-28 1999-04-28 Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
US09/380,988 US6221887B1 (en) 1998-04-28 1999-04-28 Treatment of inflammatory disorders with NMDA antagonists and sodium channel antagonists
DK99947024T DK1073431T3 (da) 1998-04-28 1999-04-28 Anvendelse af NMDA-antagonister til behandling af irritabel tarmsyndrom
NZ507436A NZ507436A (en) 1998-04-28 1999-04-28 Use of NMDA antagonists for treatment of irritable bowel syndrome (IBS) and compounds with NMDA receptor antagonistic properties
PT99947024T PT1073431E (pt) 1998-04-28 1999-04-28 Utlizacao de antagonistas de nmda no tratamento da sindroma do intestino irritavel
AU43024/99A AU760783B2 (en) 1998-04-28 1999-04-28 Use of NMDA antagonists for treatment of irritable bowel syndrome
KR1020007011958A KR100569777B1 (ko) 1998-04-28 1999-04-28 과민성 대장 증후군의 치료를 위한 ｎｍｄａ 길항제의 용도
AT99947024T ATE270545T1 (de) 1998-04-28 1999-04-28 Verwendung von nmda antagonisten zur behandlung des reizkolons
DE69918541T DE69918541T2 (de) 1998-04-28 1999-04-28 Verwendung von nmda antagonisten zur behandlung des reizkolons
ES99947024T ES2221753T3 (es) 1998-04-28 1999-04-28 Uso de antagonistas de nmda para el tratamiento del sindrome del colon irritable.
PCT/SE1999/000702 WO1999055323A1 (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome
AT99925537T ATE271861T1 (de) 1998-04-28 1999-04-28 Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
EP99925537A EP1073430B1 (en) 1998-04-28 1999-04-28 Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
IL13891999A IL138919A0 (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome
JP2000545522A JP2002512956A (ja) 1998-04-28 1999-04-28 過敏性腸症候群の治療のためのｎｍｄａアンタゴニストの使用
CNB998078182A CN1200702C (zh) 1998-04-28 1999-04-28 Nmda拮抗剂用于治疗过敏性肠综合征的用途
SI9930647T SI1073431T1 (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome
EP99947024A EP1073431B1 (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome
TW088113888A TW570793B (en) 1998-04-28 1999-08-13 Pharmaceutical composition comprising an NMDA antagonist for treating irritable bowel syndrome
SA99200482A SA99200482B1 (ar) 1998-04-28 1999-08-17 استخدام مضادات nmda في علاج متلازمة المعدة التهيجية irritable bowel syndrome
NO20005386A NO20005386D0 (no) 1998-04-28 2000-10-26 Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9801494A SE9801494D0 (sv) 1998-04-28 1998-04-28 Novel use

Publications (1)

Publication Number Publication Date
SE9801494D0 true SE9801494D0 (sv) 1998-04-28

Family

ID=20411120

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9801494A SE9801494D0 (sv) 1998-04-28 1998-04-28 Novel use

Country Status (8)

Country Link
US (1) US6221887B1 (sv)
EP (1) EP1073430B1 (sv)
JP (1) JP2002512955A (sv)
AT (1) ATE271861T1 (sv)
AU (1) AU4179399A (sv)
DE (1) DE69918972T2 (sv)
SE (1) SE9801494D0 (sv)
WO (1) WO1999055322A1 (sv)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003081872A (ja) * 2001-09-13 2003-03-19 Nippon Oruganon Kk 掻痒治療薬
US20030140920A1 (en) * 2001-10-26 2003-07-31 Dey L.P. Albuterol inhalation soultion, system, kit and method for relieving symptoms of pediatric asthma
JP2003221335A (ja) 2001-10-26 2003-08-05 Dey Lp 慢性閉塞性肺疾患の症状を緩和するためのアルブテロールおよびイプラトロピウム吸入溶液、システム、キットおよび方法
US6702997B2 (en) 2001-10-26 2004-03-09 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
US20030191151A1 (en) * 2001-10-26 2003-10-09 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
US20030203930A1 (en) * 2001-10-26 2003-10-30 Imtiaz Chaudry Albuterol and ipratropium inhalation solution, system, kit and method for relieving symptoms of chronic obstructive pulmonary disease
GB0221956D0 (en) * 2002-09-20 2002-10-30 Novartis Ag Organic compounds
WO2005018627A1 (en) * 2003-08-25 2005-03-03 Newron Pharmaceuticals, Spa Alpha-aminoamide derivatives useful as anti-inflammatory agents
SI1809271T1 (sl) * 2004-09-10 2010-10-29 Newron Pharm Spa Uporaba (R)-(halobenziloksi) benzilamino propanamidov kot selektivnih modulatorjev natrijevih in/ali kalcijevih kanalov
NZ567540A (en) 2005-12-22 2010-07-30 Newron Pharm Spa 2-Phenylethylamino derivatives as calcium and/or sodium channel modulators
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
AU2009328497A1 (en) 2008-12-19 2010-06-24 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
WO2019190822A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
WO2019190823A1 (en) 2018-03-28 2019-10-03 Vtv Therapeutics Llc Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine
CA3110582A1 (en) 2018-10-10 2020-04-16 Vtv Therapeutics Llc Metabolites of [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl}-phenoxy)-propyl]-diethyl-amine
AU2023265825A1 (en) * 2022-05-03 2024-11-07 Nocion Therapeutics, Inc. Compositions and methods for treatment of inflammatory bowel disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635530A (en) 1991-09-12 1997-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem (3S,4S)-delta-6-tetrahydrocannabinol-7-oic acids and derivatives thereof, processors for their preparation and pharmaceutical compositions containing them
US5538993A (en) * 1991-09-12 1996-07-23 Yissum Research Development Company Certain tetrahydrocannabinol-7-oic acid derivatives
ZA932761B (en) * 1992-04-28 1993-10-28 Battelle Memorial Institute Diamine derivatives and application thereof in therapeutic fields
CA2115792C (en) * 1993-03-05 2005-11-01 David J. Mayer Method for the treatment of pain
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition

Also Published As

Publication number Publication date
JP2002512955A (ja) 2002-05-08
US6221887B1 (en) 2001-04-24
WO1999055322A1 (en) 1999-11-04
DE69918972D1 (de) 2004-09-02
DE69918972T2 (de) 2005-07-28
AU4179399A (en) 1999-11-16
ATE271861T1 (de) 2004-08-15
WO1999055322A9 (en) 2000-07-27
EP1073430B1 (en) 2004-07-28
EP1073430A1 (en) 2001-02-07

Similar Documents

Publication Publication Date Title
EA199900373A2 (ru) Фармацевтические композиции
PT1109812E (pt) Pirrolobenzodiazepinas
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
EE200100483A (et) Põletikuvastaste vahenditena kasutatavad ühendid
EA200000920A1 (ru) Производные бициклических гидроксамовых кислот
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
DK0944643T3 (da) Oxyiminopregnancarbolactoner.
SE9802729D0 (sv) Novel Compounds
IT1285770B1 (it) Composti corticoidei
SE9901077D0 (sv) Novel use
SE9801494D0 (sv) Novel use
BG99177A (bg) Нови 7 бета-заместени-4-аза-5 алфа-холестанони като инхибитори на 5 алфа-редуктаза
YU11401A (sh) Lokalne farmaceutske kompozicije koje sadrže nimesulid
AR020563A1 (es) Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion
SE9903290D0 (sv) Novel compounds
ES2147973T3 (es) Estirenos alquilatados como profarmacos de inhibidores de cox-2.
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
SE9604582D0 (sv) Novel compounds
TR200200494T2 (tr) Yağlı asit sintazı inhibitörleri.
DK1073447T3 (da) N1-modificerede glycopeptider
ATE305517T1 (de) Neurotrypsin
HN1998000102A (es) Composiciones solubilizadas de sertralina
ES2154692T3 (es) Dihidrofarnesal.
SE0001631D0 (sv) New use
EA200200750A1 (ru) Новое терапевтическое применение еноксапарина